Inventor

David F. Horrobin

Inventor

Guildford, GB

Overview

1981–2007

Patent span

Human necessities

Primary field (CPC A)

Patents· 96 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes40%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%

A23LFoods, foodstuffs or non-alcoholic beverages, not otherwise provided for5%

C07CAcyclic or carbocyclic compounds5%

A61QSpecific use of cosmetics or similar toiletry preparations4%

C07DHeterocyclic compounds4%

A23DEdible oils or fats, e.g. margarines, shortenings or cooking oils3%

A23VIndexing scheme relating to foods, foodstuffs or non-alcoholic beverages and lactic or propionic acid bacteria used in foodstuffs or food preparation2%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium1%

C07JSteroids1%

PatentTitleYear

7,202,276'Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia'2007 6,989,380'Treatment of pain'2006 6,630,157'Therapeutic and dietary compositions containing essential fatty acids and bioactive disulphides'2003 6,624,195'Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid'2003 6,610,740'Polyethylene glycol esters of polyunsaturated fatty acids'2003 6,555,700'1,3-propane diol esters and ethers and methods for their use in drug delivery'2003 6,479,544'Therapeutic combinations of fatty acids'2002 6,451,788'Treatment of pain'2002 6,441,038'Treatment of fatigue, head injury and stroke'2002 6,407,075'Fatty acid treatment'2002 6,369,041'Oral combinations of hydroxocobalamin and folic acid'2002 6,331,568'Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid'2001 6,245,811'Fatty acid esters as bioactive compounds'2001 6,184,251'Use of arachidonic acid and/or docosahexanoic acid for the treatment of dyspraxia'2001 6,177,470'Methods of treatment using ascorbyl gamma linolenic acid or ascorbyl dihomo-gamma-linolenic acid'2001 6,069,168'Compositions for treatment of diabetic complications'2000 6,015,821'Nicotinic acid esters and pharmaceutical compositions containing them'2000 5,990,164'N-alkylpolyhydroxyamine salts of polyunsaturated fatty acids'1999 5,922,345'Nutrition'1999 5,888,541'Fatty acid treatment'1999 5,871,757'Stabilization of polyunsaturates'1999 5,866,703'Triglycerides'1999 5,859,055'Method of preventing occlusion of arteries'1999 5,847,000'Fatty acid derivatives'1998 5,763,484'Lipids for treatment of disease'1998 5,670,540'Triglycerides of fatty acids'1997 5,663,202'Treatment for internal radiation damage'1997 5,635,189'Tocopherols'1997 5,620,701'Methods of treatment using di-linoleoyl-mono-gamma-linolenyl glycerol'1997 5,618,558'Fatty acid treatment'1997 5,614,208'Methods of treatment using di-linoleoyl-mono-gamma-linolenyl glycerol'1997 5,603,959'Fatty acid derivatives'1997 5,604,216'Compositions containing esters of unsaturated fatty acids'1997 5,594,031'Methods and compositions for the treatment of the skin'1997 5,589,509'Methods of reducing porphyrin toxicity using fatty acids'1996 5,583,159'Treatment of internal radiation damage'1996 5,580,556'Pharmaceutical compositions containing interferons and fatty acids'1996 5,562,913'Formulation for use in smokers'1996 5,552,150'Compostions containing di-linoleoyl-mono-gamma-linolenyl-glycerol'1996 5,516,800'Schizophrenia'1996 5,516,801'Fatty acid treatment for ectopic calcium deposition'1996 5,508,307'Method for the safe administration of fatty acid'1996 5,466,841'Formulations containing unsaturated fatty acids'1995 5,422,115'Methods of treatment and devices employing lithium salts'1995 5,380,757'Method of treating vulvar dystrophy and vaginal dryness'1995 5,378,732'Method of reducing the rate of reocclusion of arteries'1995 5,328,691'Fatty acid compositions'1994 5,324,748'Method for enhancement of 1-series PG production'1994 5,318,991'Fatty acid treatment to reduce calcium excretion'1994 5,276,020'Anti-virals'1994 5,264,217'Method of increasing the total fat content of milk'1993 5,262,174'Anti-viral compositions'1993 5,252,333'Lithium salt-containing pharmaceutical compositions'1993 5,246,726'Iron-containing composition and method for treatment of cancer'1993 5,223,271'Lithium treatment'1993 5,216,142'Anti-virals'1993 5,198,468'Essential fatty acid composition'1993 5,178,873'Essential fatty acid treatment'1993 5,145,686'Topical pharmaceutical compositions'1992 5,128,152'Iron-containing compositions and method for treating cancer'1992 5,120,760'Treating tardive dyskinesia with essential fatty acid compositions'1992 5,116,871'Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis'1992 5,116,624'EFA compositions and therapy'1992 5,080,909'Anti-viral compositions'1992 4,997,657'Method for improving skin smoothness'1991 4,996,233'Method of reducing porphyrin toxicity using fatty acids'1991 4,977,187'Treating schizophrenia with essential fatty acid compositions'1990 4,970,076'Fatty acid composition'1990 4,965,075'Methods of increasing 1-series PGs in the body'1990 4,931,468'Pharmaceutical and dietary composition'1990 4,898,885'Pharmaceutica and dietary compositions'1990 4,888,326'Method of treating defective T-lymphocyte function with rutin or troxerutin in combination with .gamma.-linolenic acid or dihomo-.gamma.-linolenic acid'1989 4,886,670'Anti-viral compositions'1989 4,868,212'Pharmaceutical and dietary composition'1989 4,855,136'Therapeutic composition and method'1989 4,826,877'Pharmaceutical and dietary composition'1989 4,810,497'Pharmaceutical compositions'1989 4,806,569'Pharmaceutical and dietary composition'1989 4,758,592'Method of treating or preventing endometriosis'1988 4,753,964'Pharmaceutical compositions of lithium compounds to treat presenile or senile dementia'1988 4,738,853'Food production'1988 4,681,896'Pharmaceutical and dietary composition'1987 4,666,701'Pharmaceutical and dietary compositions'1987 4,535,093'Pharmaceutical and dietary composition'1985 RE031836'Pharmaceutical and dietary composition'1985 4,444,755'Treatment for skin disorders'1984 4,415,554'Treatment for menstrual disorders'1983 4,393,049'Treatment for obesity'1983 4,388,324'Pharmaceutical and dietary composition'1983 4,386,072'Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor'1983 4,328,243'Manic-depressive illnesses'1982 4,309,415'Method and composition for treating inflammatory disorders'1982 4,302,447'Pharmaceutical and dietary composition'1981 4,287,202'Treatment and/or prophylaxis of spasms of coronary arteries'1981 4,273,763'Pharmaceutical and dietary compositions'1981 4,248,872'Method for the treatment of anxiety'1981

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1981–1996Patents assigned to EFAMOL LTD (29)· patent assignee history

1981–1989Patents assigned to HORROBIN DAVID F (5)· patent assignee history

1981–1994Based in Montreal, CA· patent location history

1987–1999Based in Surrey, GB· patent location history

1988–2003Based in Guildford, GB· patent location history

1988–1995Based in Haslemere, GB· patent location history

1990–1997Patents assigned to EFAMOL HOLDINGS (17)· patent assignee history

1993–2003Patents assigned to SCOTIA HOLDINGS PLC (31)· patent assignee history

1999–2006Based in Stirling, GB· patent location history

2002Patents assigned to LAXDALE LTD (2)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
SCOTIA HOLDINGS PLC	31	1993–2003
EFAMOL LTD	29	1981–1996
EFAMOL HOLDINGS	17	1990–1997
HORROBIN DAVID Fself	5	1981–1989
LAXDALE LTD	2	2002

Locations

Location	Patents	Span
Guildford, GB	47	1988–2003
Montreal, CA	19	1981–1994
Stirling, GB	11	1999–2006
Surrey, GB	7	1987–1999
Haslemere, GB	4	1988–1995